Results for this period
Full year1 July 2025 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The active pharmaceutical ingredients sales business reported higher revenue and income due to increased transaction volumes resulting from the market penetration of products launched in recent years and the expanded volume share of generic drugs. In the pharmaceutical manufacturing and sales business, tablet sales declined due partly to new competitors entering the market, while prefilled syringe products and vial products for anticancer drugs remained solid, resulting in higher revenue, although segment income declined.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 30 June 2026 |
| Net Sales | ¥24,678 million (YoY +6.1%) |
| Operating profit | ¥5,476 million (YoY +2.3%) |
| Ordinary income | ¥5,521 million (YoY +2.7%) |
| Profit attributable to owners of the parent | ¥3,748 million (YoY +3.0%) |
| Net income per share | ¥89.00 |
| Operating Margin | 22.2％ |
| Equity ratio | End of the current fiscal period 78.9％ / End of previous period 77.9％ |
| Total assets | ¥39,532 million |
| Net assets | ¥31,180 million |
| Cash flows from operating activities | ¥7,592 million |
| Cash flows from investing activities | ¥-8,154 million |
| Cash flows from financing activities | ¥189 million |
| Cash and cash equivalents at end of period | ¥14,388 million |
| Full-year earnings forecast | Net Sales ¥26,700 million (YoY +8.2%) / Operating profit ¥5,270 million (YoY -3.8%) / Ordinary income ¥5,260 million (YoY -4.7%) / Profit attributable to owners of the parent ¥3,590 million (YoY -4.2%) |
| Annual Dividend Forecast | ¥18 → ¥19（+5.6%） |
| Payout ratio | 22.3％ |
| Segment revenue | API sales business ¥16,958 million (YoY +6.5%), Pharmaceutical manufacturing and marketing business ¥8,961 million (YoY +3.4%) |
| Segment profit | API sales business ¥3,312 million (YoY +3.0%), Pharmaceutical manufacturing and marketing business ¥2,123 million (YoY -0.6%) |
| Depreciation and amortization | ¥614,509 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3,552 thousand / Extraordinary loss No applicable matters. |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 42,119,980 shares |
| Treasury Shares at Period-End | 1,476 shares |
| Factors Behind Changes in Business Performance | The active pharmaceutical ingredients sales business reported higher revenue and income due to increased transaction volumes resulting from the market penetration of products launched in recent years and the expanded volume share of generic drugs. In the pharmaceutical manufacturing and sales business, tablet sales declined due partly to new competitors entering the market, while prefilled syringe products and vial products for anticancer drugs remained solid, resulting in higher revenue, although segment income declined. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the active pharmaceutical ingredients sales business, transaction volumes increased as products launched in recent years gained market penetration and generic drugs expanded their volume share. In the pharmaceutical manufacturing and sales business, tablet sales declined due partly to new competitors entering the market, while prefilled syringe products and vial products for anticancer drugs remained solid. For the next fiscal year, the company expects sales to decline due to new competitors entering the market and drug price revisions, as well as higher costs including depreciation, personnel expenses and research and development expenses.